Targeting angiogenesis for cancer (gene) therapy

Bratislava Medical Journal

Volumn 112, Issue 8, 2011, Pages 428-434

  Gardlik, R ^a   Celec, P ^a   Bernadic, M ^a  

^a Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

Author keywords

Angiogenesis; Biomedicine; Cancer treatment; Experimental animals; Gene therapy; Proangiogentic factors

Indexed keywords

ANGIOGENESIS INHIBITOR;

ANIMAL; GENE THERAPY; GENETICS; HUMAN; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); REVIEW; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; GENE THERAPY; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 80052143163     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002; 2 (10): 795-803.
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285 (21): 1182-1186.
3. Hillen F, Griffioen AW. Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev 2007; 26 (3-4): 489-502.
4. Cao Y. Angiogenesis: What can it offer for future medicine? Exp Cell Res 2010; 316 (8): 1304-1308.
5. Ferrara N. VEGF-A: a critical regulator of blood vessel growth. Eur Cytokine Netw 2009; 20 (4): 158-163.
6. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 2006; 12 (17): 5018-5022.
7. Mabjeesh NJ, Amir S. Hypoxia-inducible factor (HIF) in human tumorigenesis. Histol Histopathol 2007; 22 (5): 559-572.
8. Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362 (6423): 841-844.
9. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005; 65 (3): 671-680.
10. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994; 367 (6463): 576-579.
11. Prewett M, Huber J, Li Y et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999; 59 (20): 5209-5218.
12. Wood JM, Bold G, Buchdunger E et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60 (8): 2178-2189.
13. Holash J, Davis S, Papadopoulos N et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002; 99 (17): 11393-11398.
14. Morera Y, Bequet-Romero M, Ayala M et al. Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non-human primates. Vaccine 2010; 28 (19): 3453-3461.
15. Zhang D, Li B, Shi J et al. Suppression of Tumor Growth and Metastasis by Simultaneously Blocking Vascular Endothelial Growth Factor (VEGF)-A and VEGF-C with a Receptor-Immunoglobulin Fusion Protein. Cancer Res 2010; 70 (6): 2495-2503.
16. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006; 26 (8): 859-870.
17. Storkebaum E, Lambrechts D, Carmeliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 2004; 26 (9): 943-954.
18. Hasumi Y, Klosowska-Wardega A, Furuhashi M, Ostman A, Heldin CH, Hellberg C. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling. Int J Cancer 2007; 121 (12): 2606-2614.
19. Oliner J, Min H, Leal J et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004; 6 (5): 507-516.
20. Hashizume H, Falcon BL, Kuroda T et al. Complementary Actions of Inhibitors of Angiopoietin-2 and VEGF on Tumor Angiogenesis and Growth. Cancer Res 2010; 70 (6): 2213-2223.
21. Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res 2005; 65 (10): 3967-3979.
22. Albini A, Brigati C, Ventura A et al. Angiostatin anti-angiogenesis requires IL-12: the innate immune system as a key target. J Transl Med 2009; 7: 5.
23. Pignochino Y, Grignani G, Cavalloni G et al. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer 2009; 8: 118.
24. Iwamoto FM, Lamborn KR, Robins HI et al. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol 2010.
25. Mross K, Stefanic M, Gmehling D et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 16 (1): 311-319.
26. Blumenschein GR, Jr., Reckamp K, Stephenson GJ et al. Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. Clin Cancer Res 16 (1): 279-290.
27. Kesisis G, Broxterman H, Giaccone G. Angiogenesis inhibitors. Drug selectivity and target specificity. Curr Pharm Des 2007; 13 (27): 2795-2809.
28. Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27 (28): 4733-4740.
29. Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27 (5): 740-745.
30. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 2007; 12 (3): 356-361.
31. Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials. Acta Oncol 2010; 49 (3): 287-297.
32. Bagri A, Kouros-Mehr H, Leong KG, Plowman GD. Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale. Trends Mol Med 2010; 16 (3): 122-132.
33. Goh PP, Sze DM, Roufogalis BD. Molecular and cellular regulators of cancer angiogenesis. Curr Cancer Drug Targets 2007; 7 (8): 743-758.
34. Senger DR. Vascular endothelial growth factor: much more than an angiogenesis factor. Mol Biol Cell 21 (3): 377-379.
35. Gardlik R, Palffy R, Hodosy J, Lukacs J, Turna J, Celec P. Vectors and delivery systems in gene therapy. Med Sci Monit 2005; 11 (4): RA110-121.
36. Bondi ML, Craparo EF. Solid lipid nanoparticles for applications in gene therapy: a review of the state of the art. Expert Opin Drug Deliv 7 (1): 7-18.
37. Lu Y, Madu CO. Viral-based gene delivery and regulated gene expression for targeted cancer therapy. Expert Opin Drug Deliv 7 (1): 19-35.
38. Zhou J, Wu Y, Henderson F et al. Adenoviral gene transfer of a mutant surfactant enzyme ameliorates pseudomonas-induced lung injury. Gene Ther 2006; 13 (12): 974-985.
39. Korecka JA, Verhaagen J, Hol EM. Cell-replacement and gene therapy strategies for Parkinson's and Alzheimer's disease. Regen Med 2007; 2 (4): 425-446.
40. Badillo AT, Chung S, Zhang L, Zoltick P, Liechty KW. Lentiviral gene transfer of SDF-1alpha to wounds improves diabetic wound healing. J Surg Res 2007; 143 (1): 35-42.
41. Gridelli C, Maione P, Del Gaizo F et al. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist 2007; 12 (2): 191-200.
42. Kramer I, Lipp HP. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. J Clin Pharm Ther 2007; 32 (1): 1-14.
43. Portsmouth D, Hlavaty J, Renner M. Suicide genes for cancer therapy. Mol Aspects Med 2007; 28 (1): 4-41.
44. Both GW. Recent progress in gene-directed enzyme prodrug therapy: an emerging cancer treatment. Curr Opin Mol Ther 2009; 11 (4): 421-432.
45. Persano L, Crescenzi M, Indraccolo S. Anti-angiogenic gene therapy of cancer: current status and future prospects. Mol Aspects Med 2007; 28 (1): 87-114.
46. Tada H, Maron DJ, Choi EA et al. Systemic IFN-beta gene therapy results in long-term survival in mice with established colorectal liver metastases. J Clin Invest 2001; 108 (1): 83-95.
47. Kim WJ, Yockman JW, Jeong JH et al. Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g-PEG-RGD/pCMV-sFlt-1 complexes in tumor-bearing mice. J Control Release 2006; 114 (3): 381-388.
48. Yao B, He QM, Tian L et al. Enhanced antitumor effect of the combination of tumstatin gene therapy and gemcitabine in murine models. Hum Gene Ther 2005; 16 (9): 1075-1086.
49. Feldman AL, Friedl J, Lans TE et al. Retroviral gene transfer of interferon-inducible protein 10 inhibits growth of human melanoma xenografts. Int J Cancer 2002; 99 (1): 149-153.
50. Pfeifer A, Kessler T, Silletti S, Cheresh DA, Verma IM. Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. Proc Natl Acad Sci U S A 2000; 97 (22): 12227-12232.
51. Jazowiecka-Rakus J, Jarosz M, Szala S. Combination of vasostatin gene therapy with cyclophosphamide inhibits growth of B16(F10) melanoma tumours. Acta Biochim Pol 2006; 53 (1): 199-202.
52. Koga M, Kai H, Egami K et al. Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice. Biochem Biophys Res Commun 2008; 365 (2): 279-284.
53. Okada Y, Ueno H, Katagiri M et al. Experimental study of antian-giogenic gene therapy targeting VEGF in oral cancer. Odontology 98 (1): 52-59.
54. Zheng JN, Pei DS, Mao LJ et al. Oncolytic adenovirus expressing interleukin-18 induces significant antitumor effects against melanoma in mice through inhibition of angiogenesis. Cancer Gene Ther 17 (1): 28-36.
55. Yang L, Wang L, Su XQ et al. Suppression of ovarian cancer growth via systemic administration with liposome-encapsulated adenovirus encoding endostatin. Cancer Gene Ther 17 (1): 49-57.
56. Tysome JR, Briat A, Alusi G et al. Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer. Gene Ther 2009; 16 (10): 1223-1233.
57. Liu LL, Smith MJ, Sun BS, Wang GJ, Redmond HP, Wang JH. Combined IFN-gamma-endostatin gene therapy and radiotherapy attenuates primary breast tumor growth and lung metastases via enhanced CTL and NK cell activation and attenuated tumor angiogenesis in a murine model. Ann Surg Oncol 2009; 16 (5): 1403-1411.
58. Zhang Y, Qu ZH, Cui M et al. Combined endostatin and TRAIL gene transfer suppresses human hepatocellular carcinoma growth and angiogenesis in nude mice. Cancer Biol Ther 2009; 8 (5): 466-473.
59. Ning T, Yan X, Lu ZJ et al. Gene Therapy in Orthotopic Lung Cancer Murine Model with Angiogenesis Inhibitor, Endostatin. Hum Gene Ther 2008;
60. Sangro B, Mazzolini G, Ruiz J et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 2004; 22 (8): 1389-1397.
61. Heinzerling L, Burg G, Dummer R et al. Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. Hum Gene Ther 2005; 16 (1): 35-48.
62. Anwer K, Barnes MN, Fewell J, Lewis DH, Alvarez RD. Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer. Gene Ther 17 (3): 360-369.
63. Sterman DH, Recio A, Carroll RG et al. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res 2007; 13 (15 Pt 1): 4456-4466.
64. Kleinman ME, Yamada K, Takeda A et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008; 452 (7187): 591-597.
65. Bonauer A, Carmona G, Iwasaki M et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 2009; 324 (5935): 1710-1713.
66. Wang Z, Li Y, Kong D, Ahmad A, Banerjee S, Sarkar FH. Crosstalk between miRNA and Notch signaling pathways in tumor development and progression. Cancer Lett 2009.
67. Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev 2009; 28 (3-4): 369-378.
68. Fasanaro P, Greco S, Ivan M, Capogrossi MC, Martelli F. microRNA: emerging therapeutic targets in acute ischemic diseases. Pharmacol Ther 125 (1): 92-104.